MedTrace Logo

Hepatitis C in Prison: Study of Screening and Rapid Treatment (HEPAPRIS)

NCT05649202 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2026-05-06

No results posted yet for this study

Summary

Due to the high prevalence of HCV in prison and the risk of transmission between inmates, the management of hepatitis C and its treatment must be optimal following the recommendations of AFEF.

The purpose of this study is to assess the treatment starting delay from the date of incarceration of inmates with chronic HCV infection (hepatitis C).

Conditions

  • Chronic HIV Infection

Interventions

OTHER

Xpert® HCV Viral test

an additional sample of 5 ml of blood will be taken for real-time HCV PCR by Xpert®, in addition to the blood samples taken as part of routine care.

OTHER

FibroScan® test

A non invasive test made on a small area of skin coated with a gel

Sponsors & Collaborators

  • URC-CIC Paris Descartes Necker Cochin

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Benjamin ANDREW SILBERMANN, MsD · APHP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-31
Primary Completion
2025-01-31
Completion
2025-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05649202 on ClinicalTrials.gov